.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 6,884,439

« Back to Dashboard

Claims for Patent: 6,884,439

Title: Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
Abstract:The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.
Inventor(s): Warrell, Jr.; Raymond P. (Westfield, NJ), Pandolfi; Pier Paolo (New York, NY), Gabrilove; Janice L. (New York, NY)
Assignee: Memorial Sloan-Kettering Cancer Center (New York, NY)
Application Number:10/759,291
Patent Claims: 1. A method for treating acute promyelocytic leukemia in a human comprising administering a therapeutically effective dosage amount of about 0.15 mg/kg arsenic trioxide once per day.

2. The method of claim 1, wherein said arsenic trioxide is administered until bone marrow remission, which constitutes a first administration.

3. The method of claim 2, further comprising a second administration of a therapeutically effective dosage amount of about 0.15 mg/kg arsenic trioxide once per day for 25 doses.

4. The method of claim 3, wherein said second administration is administered 3 to 6 weeks after said first administration.

5. The method of claim 4, wherein said second administration is administered for up to five weeks.

6. The method of claim 5, wherein said second administration is administered at five doses per week.

7. The method of claim 3, further comprising repeating said second administration.

8. The method of claim 7, wherein said second administration is repeated every 3 to 6 weeks.

9. The method of claim 8, wherein said second administration is repeated until a total of between two and ten cycles of said second administration are completed.

10. The method of claim 9, further comprising repeating said second administration until a total of two cycles of said second administration are completed.

11. The method of claim 9, further comprising repeating said second administration until a total of ten cycles of said second administration are completed.

12. The method of claim 1, wherein said arsenic trioxide is administered for up to sixty days, which constitutes a first administration.

13. The method of claim 12, further comprising a second administration of a therapeutically effective dosage amount of about 0.15 mg/kg arsenic trioxide once per day for 25 doses.

14. The method of claim 13, wherein said second administration is administered 3 to 6 weeks after said first administration.

15. The method of claim 14, wherein said second administration is administered for up to five weeks.

16. The method of claim 15, wherein said second administration is administered at five doses per week.

17. The method of claim 13, further comprising repeating said second administration.

18. The method of claim 17, wherein said second administration is repeated every 3 to 6 weeks.

19. The method of claim 18, wherein said second administration is repeated until a total of between two and ten cycles of said second administration are completed.

20. The method of claim 19, further comprising repeating said second administration until a total of two cycles of said second administration are completed.

21. The method of claim 19, further comprising repeating said second administration until a total of ten cycles of said second administration are completed.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc